Nanoscope to Present 4-Year Data on MCO-010 for Retinitis Pigmentosa — Nanoscope Therapeutics Inc.

Event summary

Nanoscope Therapeutics will present 4-year follow-up data from the RESTORE Phase 2b/3 trial of MCO-010 (MOGENRY®) for retinitis pigmentosa at the 59th Annual Retina Society Meeting on September 23, 2026.
Dr. Christine Kay will present data showing sustained visual acuity gains in patients treated with MOGENRY®.
MOGENRY® is the only program to demonstrate long-term durability in restoring visual acuity, with its BLA accepted and filed by the FDA.
Nanoscope plans to initiate a Phase 3 trial for Stargardt disease in 2026 and has other IND-ready programs, including for geographic atrophy and Leber congenital amaurosis.

The big picture

Nanoscope's presentation of 4-year data for MCO-010 underscores the potential of optogenetic therapy in treating retinal degeneration. The sustained visual acuity gains could differentiate MOGENRY® in a competitive landscape, particularly if the FDA approval process moves forward smoothly. The company's broader pipeline, including programs for Stargardt disease and geographic atrophy, positions it as a key player in the retinal degeneration space.

What we're watching

Regulatory Approval: Whether the FDA will approve MOGENRY® based on the long-term durability data presented at the Retina Society Meeting.
Clinical Expansion: The pace at which Nanoscope can advance its Phase 3 trial for Stargardt disease and other IND-ready programs.
Market Potential: How sustained visual acuity gains could position MOGENRY® as a standard of care for retinitis pigmentosa and other retinal degenerative diseases.